RICHARD DOUGLAS MOORE

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. pmc Improvement in the health of HIV-infected persons in care: reducing disparities
    Richard D Moore
    Department of Medicine, Johns Hopkins University School of Medicine, 1830 E Monument St, Baltimore, MD 21287, USA
    Clin Infect Dis 55:1242-51. 2012
  2. pmc Study design and participant characteristics of a randomized controlled trial of directly administered antiretroviral therapy in opioid treatment programs
    Bernadette Anna Mullen
    Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    BMC Infect Dis 11:45. 2011
  3. pmc Identifying individuals with virologic failure after initiating effective antiretroviral therapy: The surprising value of mean corpuscular hemoglobin in a cross-sectional study
    Bryan Lau
    Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 N, Wolfe Street, Baltimore, Maryland 21205, USA
    AIDS Res Ther 7:25. 2010
  4. pmc CD4 count at presentation for HIV care in the United States and Canada: are those over 50 years more likely to have a delayed presentation?
    Keri N Althoff
    Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 N Wolfe St, Baltimore, MD, 21205, USA
    AIDS Res Ther 7:45. 2010
  5. ncbi request reprint Differences in HIV disease progression by injecting drug use in HIV-infected persons in care
    Richard D Moore
    Johns Hopkins University School of Medicine, 1830 East Monument Street, Room 8059, Baltimore, MD 21287, USA
    J Acquir Immune Defic Syndr 35:46-51. 2004
  6. pmc Epidemiology of HIV infection in the United States: implications for linkage to care
    Richard D Moore
    Department of Medicine and Infectious Diseases, Johns Hopkins University, Baltimore, Maryland 21287, USA
    Clin Infect Dis 52:S208-13. 2011
  7. pmc Association between use of HMG CoA reductase inhibitors and mortality in HIV-infected patients
    Richard D Moore
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America
    PLoS ONE 6:e21843. 2011
  8. pmc Dramatic decline in the HIV-1 RNA level over calendar time in a large urban HIV practice
    Richard D Moore
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    Clin Infect Dis 53:600-4. 2011
  9. ncbi request reprint CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression
    Richard D Moore
    Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Clin Infect Dis 44:441-6. 2007
  10. ncbi request reprint Cost-effectiveness of hydroxyurea in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia
    R D Moore
    Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    Am J Hematol 64:26-31. 2000

Research Grants

  1. North American AIDS Cohorts Collaboration on Research and Design
    Richard Moore; Fiscal Year: 2007
  2. HIV DISEASE OUTCOMES IN DRUG USERS IN CLINICAL PRACTICE
    RICHARD DOUGLAS MOORE; Fiscal Year: 2010
  3. HIV and Substance Abuse
    Richard Moore; Fiscal Year: 2007
  4. HIV DISEASE OUTCOMES IN DRUG USERS IN CLINICAL PRACTICE
    Richard Moore; Fiscal Year: 2007
  5. Alcohol and HIV Progression in the Hopkins HIV Cohort
    Richard Moore; Fiscal Year: 2005
  6. HIV DISEASE OUTCOMES IN DRUG USERS IN CLINICAL PRACTICE
    Richard Moore; Fiscal Year: 2002
  7. Alcohol and HIV Treatment and Clinical Progression
    RICHARD DOUGLAS MOORE; Fiscal Year: 2010

Collaborators

Detail Information

Publications72

  1. pmc Improvement in the health of HIV-infected persons in care: reducing disparities
    Richard D Moore
    Department of Medicine, Johns Hopkins University School of Medicine, 1830 E Monument St, Baltimore, MD 21287, USA
    Clin Infect Dis 55:1242-51. 2012
    ..Our inner-city HIV clinical practice in Baltimore has a diverse patient population with high rates of poverty, black race, and injection drug use (IDU), providing us the opportunity to compare health process and outcomes...
  2. pmc Study design and participant characteristics of a randomized controlled trial of directly administered antiretroviral therapy in opioid treatment programs
    Bernadette Anna Mullen
    Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    BMC Infect Dis 11:45. 2011
    ..Prior work from our group and others suggests that directly administered antiretroviral therapy (DAART) delivered in opioid treatment programs (OTPs) may increase rates of viral suppression...
  3. pmc Identifying individuals with virologic failure after initiating effective antiretroviral therapy: The surprising value of mean corpuscular hemoglobin in a cross-sectional study
    Bryan Lau
    Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 N, Wolfe Street, Baltimore, Maryland 21205, USA
    AIDS Res Ther 7:25. 2010
    ..We assessed whether routinely collected clinical markers could improve prediction of concurrent HIV RNA levels...
  4. pmc CD4 count at presentation for HIV care in the United States and Canada: are those over 50 years more likely to have a delayed presentation?
    Keri N Althoff
    Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 N Wolfe St, Baltimore, MD, 21205, USA
    AIDS Res Ther 7:45. 2010
    ..10%, respectively). Due to the increasing proportion, consistently lower CD4 counts, and more advanced HIV disease in adults ≥50-year-old at first presentation for HIV care, renewed HIV testing efforts are needed...
  5. ncbi request reprint Differences in HIV disease progression by injecting drug use in HIV-infected persons in care
    Richard D Moore
    Johns Hopkins University School of Medicine, 1830 East Monument Street, Room 8059, Baltimore, MD 21287, USA
    J Acquir Immune Defic Syndr 35:46-51. 2004
    ..We assessed if there were differences between HIV-infected IDUs and non-IDU patients in the development of AIDS-defining illnesses (ADIs) from the time the patients started their first combination antiretroviral therapy (CART) regimen...
  6. pmc Epidemiology of HIV infection in the United States: implications for linkage to care
    Richard D Moore
    Department of Medicine and Infectious Diseases, Johns Hopkins University, Baltimore, Maryland 21287, USA
    Clin Infect Dis 52:S208-13. 2011
    ....
  7. pmc Association between use of HMG CoA reductase inhibitors and mortality in HIV-infected patients
    Richard D Moore
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America
    PLoS ONE 6:e21843. 2011
    ..The HMG-coenzyme A reductase inhibitors (statins) inhibit several pro-inflammatory processes and suppress immune activation, and are a logical therapy to assess for a possible salutary effect on HIV disease progression and outcomes...
  8. pmc Dramatic decline in the HIV-1 RNA level over calendar time in a large urban HIV practice
    Richard D Moore
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    Clin Infect Dis 53:600-4. 2011
    ....
  9. ncbi request reprint CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression
    Richard D Moore
    Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Clin Infect Dis 44:441-6. 2007
    ..We characterized the increase in the CD4(+) cell count in patients in clinical practice who maintained sustained viral suppression for up to 6 years...
  10. ncbi request reprint Cost-effectiveness of hydroxyurea in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia
    R D Moore
    Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    Am J Hematol 64:26-31. 2000
    ..If hydroxyurea can prevent development of chronic organ damage, long-term savings may be even greater...
  11. ncbi request reprint An improvement in virologic response to highly active antiretroviral therapy in clinical practice from 1996 through 2002
    Richard D Moore
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    J Acquir Immune Defic Syndr 39:195-8. 2005
    ..This suggests that improved virologic response may also be attributable to other factors such as a greater focus on medication adherence, improved ARV tolerability, and ease of dosing...
  12. ncbi request reprint Anemia in HIV-infected patients receiving highly active antiretroviral therapy
    Richard D Moore
    Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    J Acquir Immune Defic Syndr 29:54-7. 2002
    ..Anemia is common in HIV infection, particularly in advanced disease states. We wished to determine how highly active antiretroviral therapy (HAART) and other factors affected the level of hemoglobin in HIV infection...
  13. ncbi request reprint Incidence of pancreatitis in HIV-infected patients receiving nucleoside reverse transcriptase inhibitor drugs
    R D Moore
    Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    AIDS 15:617-20. 2001
    ..We investigated the incidence of pancreatitis in patients using nucleoside analogues with or without hydroxyurea...
  14. ncbi request reprint Cost effectiveness of combination HIV therapy: 3 years later
    R D Moore
    Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Pharmacoeconomics 17:325-30. 2000
    ..Economic analyses of HIV infection must evolve in tandem with therapeutic changes to continue to be relevant to policy makers, payors of care, and those who provide and receive HIV care...
  15. pmc Rate of comorbidities not related to HIV infection or AIDS among HIV-infected patients, by CD4 cell count and HAART use status
    Richard D Moore
    Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Clin Infect Dis 47:1102-4. 2008
    ..Among patients with a CD4 cell count <350 cells/mm(3), receipt of HAART was associated with a significantly decreased incidence of comorbidities not related to HIV infection or AIDS...
  16. pmc Effect of age and HAART regimen on clinical response in an urban cohort of HIV-infected individuals
    Adena H Greenbaum
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    AIDS 22:2331-9. 2008
    ..Some earlier studies suggest that older patients respond differently to HAART than younger patients. The objective of this study is to compare the effectiveness of HAART in older and younger HIV patients...
  17. ncbi request reprint Hospital and outpatient health services utilization among HIV-infected adults in care 2000-2002
    John A Fleishman
    Agency for Healthcare Research and Quality, Rockville, Maryland, USA
    Med Care 43:III40-52. 2005
    ..Rapid changes in HIV epidemiology and antiretroviral therapy may have resulted in recent changes in patterns of healthcare utilization...
  18. pmc A ten-year analysis of the incidence and risk factors for acute pancreatitis requiring hospitalization in an urban HIV clinical cohort
    David J Riedel
    Institute of Human Virology and Division of Infectious Diseases, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
    AIDS Patient Care STDS 22:113-21. 2008
    ..Of note, newer antiretrovirals, particularly atazanavir, lopinivir/ritonavir, tenofovir, abacavir, and efavirenz, were not associated with an increased risk of pancreatitis...
  19. ncbi request reprint The effect of HAART and HCV infection on the development of hyperglycemia among HIV-infected persons
    Shruti H Mehta
    Department of Epidemiology, Johns Hopkins University, Baltimore, Maryland 21287, USA
    J Acquir Immune Defic Syndr 33:577-84. 2003
    ..DESIGN Retrospective cohort analysis of 1230 persons on their first HAART regimen who had at least 1 random glucose measurement before and during antiretroviral therapy...
  20. pmc The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil
    Jonathan E Golub
    Center for Tuberculosis Research, Johns Hopkins University, Baltimore, Maryland 21231, USA
    AIDS 21:1441-8. 2007
    ..Antiretroviral therapy (ART) lowers the risk of tuberculosis, but may not be sufficient to control HIV-related tuberculosis. Isoniazid preventive therapy (IPT) reduces tuberculosis incidence significantly, but is not widely used...
  21. ncbi request reprint Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance
    Ajay K Sethi
    Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
    Clin Infect Dis 37:1112-8. 2003
    ..Clinicians and patients must set high adherence goals to avoid the development of resistance...
  22. ncbi request reprint Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic
    Gregory M Lucas
    Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    AIDS 16:767-74. 2002
    ..To assess the temporal association of changes in substance abuse with antiretroviral therapy use and adherence, HIV-1 RNA suppression, and CD4 cell count changes in patients attending an urban clinic...
  23. ncbi request reprint Mycobacterium avium complex in patients with HIV infection in the era of highly active antiretroviral therapy
    Petros C Karakousis
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21231 1003, USA
    Lancet Infect Dis 4:557-65. 2004
    ..Although HAART has altered the frequency and outcome of MAC infection, it remains an important complication of AIDS...
  24. pmc HIV women's health: a study of gynecological healthcare service utilization in a U.S. urban clinic population
    Monique A Tello
    Department of Medicine, Division of General Internal Medicine, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    J Womens Health (Larchmt) 17:1609-14. 2008
    ..Women infected with HIV have a high rate of many gynecological problems. Adherence to recommended gynecological care among women enrolled in our urban HIV clinics was hypothesized to be low...
  25. ncbi request reprint The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis C coinfection
    Shruti H Mehta
    Department of Epidemiology, Johns Hopkins School of Public Health, Baltimore, MD 21205 0003, USA
    Hepatology 41:123-31. 2005
    ..Recognition of bridging fibrosis and cirrhosis in some but not most patients underscores the importance of identifying and treating liver disease in HIV/HCV coinfected persons...
  26. pmc HIV-1 diversity after a class switch failure
    Michael A Kolber
    Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida 33136, USA
    AIDS Res Hum Retroviruses 26:1175-80. 2010
    ..The development of HIV viral diversity after multiple HAART failures is determined by the sequence in which the regimens are ordered...
  27. pmc Association of medical insurance and other factors with receipt of antiretroviral therapy
    Jeanne C Keruly
    Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    Am J Public Health 92:852-7. 2002
    ..This study was designed to assess sociodemographic and medical insurer factors associated with receipt of highly active antiretroviral therapy (HAART)...
  28. ncbi request reprint Genotypic resistance in HIV-1-infected patients with persistently detectable low-level viremia while receiving highly active antiretroviral therapy
    Richard E Nettles
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    Clin Infect Dis 39:1030-7. 2004
    ....
  29. ncbi request reprint End-stage renal disease and chronic kidney disease in a cohort of African-American HIV-infected and at-risk HIV-seronegative participants followed between 1988 and 2004
    Gregory M Lucas
    Department of Medicine, Divisions of Infectious Diseases, Bloomberg School of Public Health, John Hopkins University, Baltimore, Maryland, USA
    AIDS 21:2435-43. 2007
    ..HIV-infected African-Americans are at increased risk of end-stage renal disease requiring renal replacement therapy (RRT)...
  30. pmc Racial and sex disparities in life expectancy losses among HIV-infected persons in the united states: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy
    Elena Losina
    Divisions of General Medicine, Department of Medicine, MA 02114, USA
    Clin Infect Dis 49:1570-8. 2009
    ....
  31. pmc Is the quality of the patient-provider relationship associated with better adherence and health outcomes for patients with HIV?
    Mary Catherine Beach
    Division of General Internal Medicine, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    J Gen Intern Med 21:661-5. 2006
    ....
  32. ncbi request reprint Does the presence of a current psychiatric disorder in AIDS patients affect the initiation of antiretroviral treatment and duration of therapy?
    Seth Himelhoch
    Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD 21287, USA
    J Acquir Immune Defic Syndr 37:1457-63. 2004
    ..We investigated whether a current psychiatric disorder (1) affected the time to initiation of HAART, (2) predicted the likelihood of being prescribed HAART for at least 6 months, and (3) affected survival in urban AIDS patients...
  33. ncbi request reprint Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults
    Mark S Sulkowski
    Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    AIDS 21:2209-16. 2007
    ....
  34. pmc Impact of patient race on patient experiences of access and communication in HIV care
    P Todd Korthuis
    Department of Medicine, Oregon Health and Science University, Portland, OR 97239 3098, USA
    J Gen Intern Med 23:2046-52. 2008
    ..Patient-centered care--including the domains of access and communication--is an important determinant of positive clinical outcomes...
  35. ncbi request reprint Immune reconstitution inflammatory syndrome: risk factors and treatment implications
    Yukari C Manabe
    Center for Tuberculosis Research, Division of Infectious Diseases, School of Medicine, Johns Hopkins University, Baltimore, MD 21231, USA
    J Acquir Immune Defic Syndr 46:456-62. 2007
    ..We sought to determine clinical risk factors for the development of IRIS...
  36. doi request reprint Survival during renal replacement therapy among African Americans infected with HIV type 1 in urban Baltimore, Maryland
    Mohamed G Atta
    Division of Nephrology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Clin Infect Dis 45:1625-32. 2007
    ..It is unknown how the widespread use of highly active antiretroviral therapy (HAART) has affected survival during RRT in this vulnerable population...
  37. pmc Venous thromboembolism in patients with HIV/AIDS: a case-control study
    Aima A Ahonkhai
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    J Acquir Immune Defic Syndr 48:310-4. 2008
    ..We investigated the prevalence of established risk factors for VTE in this population and explored novel risk factors...
  38. pmc HAART receipt and viral suppression among HIV-infected patients with co-occurring mental illness and illicit drug use
    Geetanjali Chander
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    AIDS Care 21:655-63. 2009
    ..Co-occurring MI and DU is associated with lower HAART receipt and viral suppression compared to individuals with either MI or DU or neither. Integrating HIV, substance abuse, and mental healthcare may improve outcomes in this population...
  39. pmc Chronic kidney disease incidence, and progression to end-stage renal disease, in HIV-infected individuals: a tale of two races
    Gregory M Lucas
    Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicines, Baltimore, Maryland, USA
    J Infect Dis 197:1548-57. 2008
    ..Little is known about the racial differences in the incidence and progression of HIV-related chronic kidney disease (CKD) that underlie African American-white disparities in HIV-related end-stage renal disease (ESRD)...
  40. pmc Gonorrhoea and chlamydia testing rates of HIV-infected men: low despite guidelines
    Stephen A Berry
    Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD 21287 2100, USA
    Sex Transm Infect 86:481-4. 2010
    ..This study determined GC/CT testing rates in a clinical HIV cohort before and after 2003 when the US Centers for Disease Control and Prevention issued guidelines for GC/CT screening...
  41. pmc Clinic-based treatment of opioid-dependent HIV-infected patients versus referral to an opioid treatment program: A randomized trial
    Gregory M Lucas
    Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Ann Intern Med 152:704-11. 2010
    ..Opioid dependence is common in HIV clinics. Buprenorphine-naloxone (BUP) is an effective treatment of opioid dependence that may be used in routine medical settings...
  42. pmc Assessment of liver fibrosis by transient elastography in persons with hepatitis C virus infection or HIV-hepatitis C virus coinfection
    Gregory D Kirk
    Department of Epidemiology, Schools of Public Health and Medicine, Johns Hopkins University, Baltimore, Maryland 21205, USA
    Clin Infect Dis 48:963-72. 2009
    ..We compared elastography with histologic methods among hepatitis C virus (HCV)-infected and human immunodeficiency virus (HIV)-HCV-coinfected participants in an urban, predominantly black study population...
  43. pmc Renal function with use of a tenofovir-containing initial antiretroviral regimen
    Joel E Gallant
    Department of Medicine, Johns Hopkins University School of Medicine, 1830 E Monument Street, Baltimore, MD 21205, USA
    AIDS 23:1971-5. 2009
    ....
  44. pmc Inpatient health services utilization among HIV-infected adult patients in care 2002-2007
    Baligh R Yehia
    Johns Hopkins University School of Medicine, 1830 E Monument St, Room 435, Baltimore, MD 21287, USA
    J Acquir Immune Defic Syndr 53:397-404. 2010
    ..This study examines the frequency of inpatient hospitalization, the number of inpatient days, and factors associated with inpatient utilization in a multistate HIV cohort between 2002 and 2007...
  45. ncbi request reprint Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment
    Joel E Gallant
    The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    Clin Infect Dis 40:1194-8. 2005
    ..Other associations included a lower CD4 cell count, decreased renal function at baseline, and diabetes. The declines were modest and did not lead to greater rates of discontinuation of therapy...
  46. ncbi request reprint Immune status at presentation to care did not improve among antiretroviral-naive persons from 1990 to 2006
    Jeanne C Keruly
    Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    Clin Infect Dis 45:1369-74. 2007
    ..Late presentation may increase the risk of HIV transmission and make HIV infection more difficult to treat effectively. With more effective HIV therapy, it was hoped that patients might present earlier in their disease course...
  47. ncbi request reprint Treatment of HIV infection in the older patient
    Kelly A Gebo
    John Hopkins University School of Medicine, Epidemiology, 1830 E Monument Street, Room 442, Baltimore, MD 21205, USA
    Expert Rev Anti Infect Ther 2:733-43. 2004
    ....
  48. ncbi request reprint Directly administered antiretroviral therapy in an urban methadone maintenance clinic: a nonrandomized comparative study
    Gregory M Lucas
    Johns Hopkins University, Baltimore, MD 21287, USA
    Clin Infect Dis 38:S409-13. 2004
    ..008). The preliminary results of this study both suggest that DAART can be feasible and acceptable to patients in a methadone clinic setting and provide impetus for further study of this treatment strategy in randomized controlled trials...
  49. ncbi request reprint Highly active antiretroviral therapy and the incidence of HIV-1-associated nephropathy: a 12-year cohort study
    Gregory M Lucas
    Johns Hopkins University, Baltimore and the Good Samaritan Hospital, Baltimore, Maryland, USA
    AIDS 18:541-6. 2004
    ..to assess temporal changes in the incidence of human immunodeficiency virus-1-associated nephropathy (HIVAN), and the association with use of highly active antiretroviral therapy (HAART)...
  50. ncbi request reprint Improved outcomes with earlier initiation of highly active antiretroviral therapy among human immunodeficiency virus-infected patients who achieve durable virologic suppression: longer follow-up of an observational cohort study
    Timothy R Sterling
    Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    J Infect Dis 188:1659-65. 2003
    ..Initiating HAART with a CD4+ lymphocyte count of <200 cells/mm3 was associated with a higher risk of disease progression, even with durable virologic suppression. HAART should be initiated at CD4+ lymphocyte counts of >200 cells/mm3...
  51. ncbi request reprint Hospitalization rates differ by hepatitis C satus in an urban HIV cohort
    Kelly A Gebo
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    J Acquir Immune Defic Syndr 34:165-73. 2003
    ..To determine whether hepatitis C virus (HCV) infection status affected hospitalization rates, intensive care utilization rates, and discharge diagnoses between 1995 and 2000 in patients with HIV...
  52. ncbi request reprint Survival in an urban HIV-1 clinic in the era of highly active antiretroviral therapy: a 5-year cohort study
    Gregory M Lucas
    Johns Hopkins University, Baltilmore, Maryland 21287, USA
    J Acquir Immune Defic Syndr 33:321-8. 2003
    ..To examine the implications of early virologic response to highly active antiretroviral therapy (HAART) on long-term HAART utilization patterns, development of diabetes or hyperlipidemia, and mortality in an urban HIV-1 clinic...
  53. ncbi request reprint Total lymphocyte count and hemoglobin combined in an algorithm to initiate the use of highly active antiretroviral therapy in resource-limited settings
    Lisa A Spacek
    Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    AIDS 17:1311-7. 2003
    ..To develop clinical algorithms that improve the sensitivity of surrogate markers to initiate the use of highly active antiretroviral therapy (HAART) in resource-limited settings...
  54. ncbi request reprint Initiation of highly active antiretroviral therapy at CD4+ T lymphocyte counts of >350 cells/mm3: disease progression, treatment durability, and drug toxicity
    Timothy R Sterling
    Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Clin Infect Dis 36:812-5. 2003
    ..These findings support the recommendation that HAART not be initiated for patients with CD4(+) cell counts of >350 cells/mm(3)...
  55. pmc Association of social stress, illicit drug use, and health beliefs with nonadherence to antiretroviral therapy
    Kelly A Gebo
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    J Gen Intern Med 18:104-11. 2003
    ..To assess the roles of socioeconomic status, social stability, social stress, health beliefs, and illicit drug use with nonadherence to antiretroviral therapy...
  56. ncbi request reprint Greater effect of highly active antiretroviral therapy on survival in people aged > or =50 years compared with younger people in an urban observational cohort
    John L Perez
    Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    Clin Infect Dis 36:212-8. 2003
    ..28 (95% CI, 0.15-0.52) for treated older adults. The effect of HAART substantially improves the survival rate for older individuals and supports the importance of treatment in this group...
  57. ncbi request reprint Hepatitis C and progression of HIV disease
    Mark S Sulkowski
    Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, 1830 E Monument St, Room 448, Baltimore, MD 21287 0003, USA
    JAMA 288:199-206. 2002
    ..Conflicting reports exist regarding the effect of hepatitis C virus (HCV) on the progression of human immunodeficiency virus (HIV) disease...
  58. ncbi request reprint Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir
    Mark S Sulkowski
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    AIDS 18:2277-84. 2004
    ....
  59. ncbi request reprint Racial and gender disparities in receipt of highly active antiretroviral therapy persist in a multistate sample of HIV patients in 2001
    Kelly A Gebo
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    J Acquir Immune Defic Syndr 38:96-103. 2005
    ..We examined whether demographic disparities in the use of HAART persist in 2001 and if outpatient care is associated with HAART utilization...
  60. ncbi request reprint Adherence, drug use, and treatment failure in a methadone-clinic-based program of directly administered antiretroviral therapy
    Gregory M Lucas
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    AIDS Patient Care STDS 21:564-74. 2007
    ..Given that a relatively small proportion of the total ART doses were supervised in many patients, future studies should assess how DAART affects adherence with nonsupervised doses and retention to ART...
  61. ncbi request reprint Interval and clinical cohort studies: epidemiological issues
    Bryan Lau
    Division of General Internal Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21218, USA
    AIDS Res Hum Retroviruses 23:769-76. 2007
    ..The interval and clinical cohort designs are distinguished and the advantages and disadvantages inherent in each design are discussed...
  62. pmc Is patients' preferred involvement in health decisions related to outcomes for patients with HIV?
    Mary Catherine Beach
    Division of General Internal Medicine, Department of Medicine, Johns Hopkins University School of Medicine, 2024 East Monument Street, Suite 2 500, Baltimore, MD 21287, USA
    J Gen Intern Med 22:1119-24. 2007
    ..Previous studies suggest that patients who are more involved in their medical care have better outcomes...
  63. ncbi request reprint Stability of the latent reservoir for HIV-1 in patients receiving valproic acid
    Janet D Siliciano
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA
    J Infect Dis 195:833-6. 2007
    ..We conclude that the clinical use of VA has no ancillary effect on the decay of the latent reservoir...
  64. ncbi request reprint Incidence of, risk factors for, clinical presentation, and 1-year outcomes of infective endocarditis in an urban HIV cohort
    Kelly A Gebo
    Department of Medicine, Johns Hopkins University School of Medicine, 1830 E Monument Street, Baltimore, MD 21205, USA
    J Acquir Immune Defic Syndr 43:426-32. 2006
    ..We evaluated the incidence of, risk factors for, clinical presentation, and 1-year outcomes of IE in HIV-infected patients...
  65. pmc Hazardous alcohol use: a risk factor for non-adherence and lack of suppression in HIV infection
    Geetanjali Chander
    Department of Medicine, Johns Hopkins University School of Medicine, 1830 E Monument Street, Baltimore, MD 21287, USA
    J Acquir Immune Defic Syndr 43:411-7. 2006
    ..We examined the independent effect of alcohol and combined effects of drug and alcohol use on antiretroviral (ART) utilization, adherence, and viral suppression in an urban cohort of HIV-infected individuals...
  66. ncbi request reprint Delayed diagnosis and elevated mortality in an urban population with HIV and lung cancer: implications for patient care
    Malcolm V Brock
    Johns Hopkins Hospital, and Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21287, USA
    J Acquir Immune Defic Syndr 43:47-55. 2006
    ..Lung cancer is more common in HIV-infected patients than in the general population. We examined how effectively lung cancer was being diagnosed in our HIV-infected patients...
  67. ncbi request reprint Substance abuse and psychiatric disorders in HIV-positive patients: epidemiology and impact on antiretroviral therapy
    Geetanjali Chander
    Department of Medicine, Johns Hopkins University School of Medicine, 1830 E Monument Street, Baltimore, MD 21287, USA
    Drugs 66:769-89. 2006
    ..Future studies examining individual substances of abuse, psychiatric disorders and co-occurring substance abuse and psychiatric disorders on HIV outcomes will inform targeted adherence interventions...
  68. ncbi request reprint Directly administered antiretroviral therapy in methadone clinics is associated with improved HIV treatment outcomes, compared with outcomes among concurrent comparison groups
    Gregory M Lucas
    Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA
    Clin Infect Dis 42:1628-35. 2006
    ..Directly administered antiretroviral therapy (DAART) in methadone clinics has the potential to improve treatment outcomes for human immunodeficiency virus (HIV)-infected injection drug users (IDUs)...
  69. ncbi request reprint Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda
    Lisa A Spacek
    Johns Hopkins Medical Institutions, Baltimore, MD 21287, USA
    Clin Infect Dis 42:252-9. 2006
    ..We evaluated clinical, behavioral, and demographic risk factors associated with virologic suppression in a public, urban clinic in Kampala, Uganda...
  70. ncbi request reprint Hospitalizations for metabolic conditions, opportunistic infections, and injection drug use among HIV patients: trends between 1996 and 2000 in 12 states
    Kelly A Gebo
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    J Acquir Immune Defic Syndr 40:609-16. 2005
    ..Rapid changes in HIV epidemiology and highly active antiretroviral therapy (HAART) may have resulted in recent changes in patterns of inpatient utilization...
  71. ncbi request reprint Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections
    Mark S Sulkowski
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD21205, USA
    Hepatology 35:182-9. 2002
    ..Severe hepatotoxicity occurs throughout the course of NNRTI therapy and is more common among patients prescribed nevirapine, those coinfected with HCV or HBV, and those coadministered protease inhibitors...
  72. pmc Alcohol consumption among HIV-infected women: impact on time to antiretroviral therapy and survival
    Robyn C Neblett
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    J Womens Health (Larchmt) 20:279-86. 2011
    ..We sought to determine factors associated with alcohol use among HIV-infected women engaged in clinical care and if baseline alcohol use was associated with time to combination antiretroviral therapy (cART) and death in this population...

Research Grants18

  1. North American AIDS Cohorts Collaboration on Research and Design
    Richard Moore; Fiscal Year: 2007
    ..e., Western Europe), and will inform future HIV practice as it evolves in transitional and developing regions. ..
  2. HIV DISEASE OUTCOMES IN DRUG USERS IN CLINICAL PRACTICE
    RICHARD DOUGLAS MOORE; Fiscal Year: 2010
    ..We propose to study to compare the outcomes of HIV therapy in injecting drug using vs. non-drug using patients as the use of highly active antiretroviral therapy is now in its second decade. ..
  3. HIV and Substance Abuse
    Richard Moore; Fiscal Year: 2007
    ..Renewal of the K24 Award will support continued research productivity and mentoring to improve care of the HIV-infected IDU. ..
  4. HIV DISEASE OUTCOMES IN DRUG USERS IN CLINICAL PRACTICE
    Richard Moore; Fiscal Year: 2007
    ..We offer a productive resource to address our aims that is unique in scope and size, cost-efficient in conducting research, highly relevant to the HIV epidemic as it effects DUs, and fully operational from our prior R01. ..
  5. Alcohol and HIV Progression in the Hopkins HIV Cohort
    Richard Moore; Fiscal Year: 2005
    ..We believe that our research will yield valuable results to better understand the relationship between alcohol use and HIV/AIDS. ..
  6. HIV DISEASE OUTCOMES IN DRUG USERS IN CLINICAL PRACTICE
    Richard Moore; Fiscal Year: 2002
    ....
  7. Alcohol and HIV Treatment and Clinical Progression
    RICHARD DOUGLAS MOORE; Fiscal Year: 2010
    ..Our study is designed to measure alcohol use in a population of HIV- infected patients in care, and to determine levels of alcohol use that increase the risk of bad outcomes. ..